Phosphorus Dendrimer Nanovaccine‐Triggered Multi‐Cell Immune Cascade for Innate and Adaptive Immune Activation and Augmented Tumor Immunotherapy
Advanced Healthcare Materials · 17.11.2026
DOI: 10.1002/adhm.71982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 17.11.2026. Verfasst von Wenyu Xie und 9 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Development of a nanovaccine (NV) that can simultaneously manipulate multiple immune cell types to activate both adaptive and innate immunity still remains a great challenge. In this study, we employed a phosphorus dendrimer (termed AK38, generation 0) with intrinsic NK cell‐proliferative activity as a carrier to complex model antigen ovalbumin (OVA) and load agonist imiquimod (R837), followed by cancer cell membrane coating. The resulting AK38‐OVA/R837@CM NV exhibits spherical morphology, stimuli‐responsive release, excellent colloidal stability, and cytocompatibility. It promotes dendritic cell (DC) maturation and enhances antigen cross‐presentation by integrating cancer cell membrane antigens, OVA, and adjuvant. Meanwhile, the NV polarizes tumor‐associated macrophages (TAMs) toward the antitumor M1 phenotype, reversing immunosuppression. Importantly, the phosphorus dendrimer enables NK cell proliferation to induce tumor apoptosis. The NV synergistically activates DCs, TAMs, and NK cells, eliciting cytotoxic T lymphocyte‐mediated adaptive immunity while enhancing TAM‐ and NK‐dominated innate responses. This was validated in a murine melanoma model, where the NV effectively inhibited tumor growth and recurrence. With its simple composition and multi‐cell immune cascade modulation, this phosphorus dendrimer‐based NV offers a versatile tumor immunotherapy strategy, showing great promise for broad cancer treatment applications by mimicking biological systems to induce robust immune responses.
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Xie, W., Sun, H., Zou, Y., Wang, Z., Li, A., Ji, R., Mignani, S., Majoral, J., Shi, X., & Shen, M. (2026). Phosphorus Dendrimer Nanovaccine‐Triggered Multi‐Cell Immune Cascade for Innate and Adaptive Immune Activation and Augmented Tumor Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71982
Vancouver
Xie W, Sun H, Zou Y, Wang Z, Li A, Ji R, et al. Phosphorus Dendrimer Nanovaccine‐Triggered Multi‐Cell Immune Cascade for Innate and Adaptive Immune Activation and Augmented Tumor Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71982
BibTeX
@article{Xie2026,
author = {Xie, Wenyu and Sun, Huxiao and Zou, Yu and Wang, Zhiqiang and Li, Aiyu and Ji, Ruiqi and Mignani, Serge and Majoral, Jean‐Pierre and Shi, Xiangyang and Shen, Mingwu},
title = {Phosphorus Dendrimer Nanovaccine‐Triggered Multi‐Cell Immune Cascade for Innate and Adaptive Immune Activation and Augmented Tumor Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71982}
}
EUVIMED